Pharmaceutical Technology

JULY 21, 2022

Listed below are the key technology trends impacting the ESG performance in the healthcare sector, as identified by GlobalData. The healthcare industry is vulnerable to cyberattacks due to the amount of valuable and sensitive data it produces. Artificial intelligence (AI). Cybersecurity and ESG.

Food and Drug Administration 98

Food and Drug Administration Government Pharma Healthcare 98

Pharmaceutical Technology

JUNE 6, 2023

The global pharma industry experienced an 11% rise in social media posts on regenerative medicine in Q1 2023 compared with the previous quarter, with the highest share accounted for Pfizer, according to GlobalData’s analysis of social media posts. Buy the report here.

Media 40

Media Medicine Pharma Medical 40

Pharmaceutical Technology

JULY 19, 2022

All aspects of environmental, social, and governance (ESG) are important, and in the healthcare industry, companies must excel across all three. Listed below are the impact of ESG on healthcare, as identified by GlobalData. The post ESG Top Trends: Healthcare ESG Impact appeared first on Pharmaceutical Technology.

Healthcare 64

Healthcare Healthcare Government Healthcare Provider 64

Pharmaceutical Technology

FEBRUARY 28, 2023

According to GlobalData, Phase I drugs for Melanoma have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how KFA-115’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Prescription 68

Prescription Pharmaceutical products Networking Manufacturing 68

Pharmaceutical Technology

FEBRUARY 24, 2023

According to GlobalData, Phase III drugs for Type 2 Diabetes have a 53% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how (LAI-287 + semaglutide)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

Manufacturing 72

Manufacturing Medicine Healthcare Healthcare 72

Pharmaceutical Technology

MAY 31, 2023

According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ZNA-1041’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Medicine 52

Medicine Healthcare Healthcare Management 52

Pharmaceutical Technology

MAY 9, 2023

The key social themes, commitment details of leading companies to social responsibility, and discussions and hiring activity for social responsibility in Healthcare and 15 other key sectors are covered in GlobalData’s Social Responsibility Trends by Sector – Thematic Intelligence report. Buy the report here.

Pharmaceutical 45

Pharmaceutical Leads Healthcare Healthcare 45

Pharmaceutical Technology

NOVEMBER 22, 2022

Drug shortages continue to affect medical care in healthcare systems, and experts tell us that supply bottlenecks for cardiovascular drugs are particularly concerning. All this, and the latest pharma industry news , comment, data, and analysis from GlobalData. Click here to view the latest issue of Pharmaceutical Technology Focus.

Pharma 93

Pharma Electronics Pharmaceutical Healthcare 93

Pharmaceutical Technology

APRIL 3, 2023

But while the pandemic hampered access to health care services, it also led to accelerated demand for digital health technologies that enabled women to access remote care during lockdowns, said Wafaa Hasan, GlobalData’s healthcare analyst at a Femtech-centric webinar held on March 30.

Physicians 52

Physicians Healthcare Healthcare Marketing 52

Pharmaceutical Technology

MAY 29, 2023

The global pharmaceutical industry experienced a 24% drop in company filings mentions of regenerative medicine in Q1 2023 compared with the previous quarter, with the highest share accounted for by Sarepta Therapeutics with 20% year-on-year decrease, according to GlobalData’s analysis of over 578 pharmaceutical company filings.

Medicine 40

Medicine Pharmaceutical Medical Healthcare 40

Pharmaceutical Technology

MARCH 22, 2023

Healthcare providers are under pressure to address the growing issue of substance use disorders. According to GlobalData’s Medical Device Pipeline Analytics, there are 61 products in development for treating substance abuse disorders classed as healthcare IT.

Food and Drug Administration 52

Food and Drug Administration Healthcare Healthcare Medical 52

Pharmaceutical Technology

MAY 9, 2023

The key social themes, commitment details of leading companies to social responsibility, and discussions and hiring activity for social responsibility in Healthcare and 15 other key sectors are covered in GlobalData’s Social Responsibility Trends by Sector – Thematic Intelligence report. Buy the report here.

Pharmaceutical 40

Pharmaceutical Leads Healthcare Healthcare 40

Pharmaceutical Technology

MARCH 2, 2023

According to GlobalData, Phase I drugs for Relapsed Acute Myeloid Leukemia have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how QN-023a’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

Engineering 40

Engineering Healthcare Healthcare Pharmaceutical 40

Pharmaceutical Technology

JULY 28, 2022

While all three agents are currently undergoing Phase III trials, GlobalData expects Eli Lilly’s mirikizumab to be the first IL-23-specific inhibitor to be approved for this indication. GlobalData expects regulatory approval of mirikizumab for UC in the US and European Union (EU) next year.

Food and Drug Administration 98

Food and Drug Administration Safety Side effects Marketing 98

Pharmaceutical Technology

APRIL 13, 2023

Following the increased use of telemedicine during the Covid-19 pandemic, the potential of digital technologies in communication, data collection, and analysis has become increasingly realised by patients, healthcare systems, and clinical trial sponsors.

Food and Drug Administration 52

Food and Drug Administration Electronics Healthcare Healthcare 52

Pharmaceutical Technology

MARCH 2, 2023

According to GlobalData, Phase I drugs for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. Hangzhou Qihan Biotechnology overview Hangzhou Qihan Biotechnology is a healthcare company. Buy the report here.

Healthcare 40

Healthcare Healthcare Pharmaceutical 40

Pharmaceutical Technology

JULY 21, 2022

As part of ESG (Environmental, Social, and Governance), the social good delivered by robust healthcare systems are at the core of healthy populations. The Covid-19 pandemic has demonstrated how vital patient access to quality and affordable healthcare is for patients all over the world. Climate change and ESG.

Government 52

Government Healthcare Healthcare Pharma 52

Pharmaceutical Technology

FEBRUARY 28, 2023

According to GlobalData, Phase I drugs for Malignant Mesothelioma have a 77% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how KFA-115’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

Prescription 40

Prescription Pharmaceutical products Networking Manufacturing 40

Pharmaceutical Technology

DECEMBER 7, 2022

On 29 November, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) warned of some new and potentially serious eye-related side effects associated with Dupixent, an interleukin (IL)-4/13 inhibitor drug used in the treatment of numerous allergic indications such as atopic dermatitis, asthma and nasal polyps.

Side effects 64

Side effects Food and Drug Administration Safety Physicians 64

Pharmaceutical Technology

FEBRUARY 20, 2023

According to GlobalData, Phase II drugs for Systemic Sclerosis (Scleroderma) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BI-685509’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

Manufacturing 40

Manufacturing Pharmaceutical Medical Healthcare 40

Pharmaceutical Technology

JUNE 5, 2023

According to GlobalData, Phase I drugs for Hypopharyngeal Cancer does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the BI-765063 LoA Report. Buy the report here.

Manufacturing 40

Manufacturing Pharmaceutical Medical Healthcare 40

Pharmaceutical Technology

FEBRUARY 28, 2023

According to GlobalData, Phase III drugs for Paroxysmal Nocturnal Hemoglobinuria have a 60% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. Iptacopan hydrochloride is under clinical development by Novartis and currently in Phase III for Paroxysmal Nocturnal Hemoglobinuria. Buy the report here.

Prescription 40

Prescription Pharmaceutical products Networking Pharmaceutical 40

Pharmaceutical Technology

FEBRUARY 28, 2023

According to GlobalData, Phase III drugs for Glomerulonephritis have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Iptacopan hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

Prescription 40

Prescription Pharmaceutical products Networking Pharmaceutical 40

Pharmaceutical Technology

JULY 28, 2022

Despite this, some key opinion leaders (KOLs) interviewed by GlobalData argued that LAIs should be prescribed as soon as possible, following first-episode psychosis or during early-stage schizophrenia. GlobalData forecasts that it will launch in the US and 5EU next year.

Prescription 98

Prescription Side effects Patients Management 98

Pharmaceutical Technology

OCTOBER 26, 2022

On October 6, in a GlobalData webinar, experts tried to answer the question ‘ Is Pharma at an ESG turning point?’ , revealing a multitude of diverse strategies for pharmaceutical companies to remain conscious of their global impacts. GlobalData is the parent company of Pharmaceutical Technology. Health disparities today.

Government 64

Government Pharmaceutical Pharma Healthcare 64

Pharmaceutical Technology

MARCH 1, 2023

According to GlobalData, Phase I drugs for Neuroendocrine Tumors have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Nedisertib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

Prescription 40

Prescription Manufacturing Healthcare Healthcare 40

Pharmaceutical Technology

MARCH 1, 2023

According to GlobalData, Phase I drugs for Head And Neck Cancer Squamous Cell Carcinoma have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Nedisertib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

Prescription 40

Prescription Manufacturing Healthcare Healthcare 40

Pharmaceutical Technology

JULY 25, 2022

The COVID-19 pandemic triggered significant changes to the way healthcare operates. According to Tom Lenaerts, Head of Global Process Engineering at Datwyler, this transformation will reshape the entire healthcare ecosystem. Many organizations are busy planning or executing digital strategies, and the supply chain is no exception.

Pharmaceutical 114

Pharmaceutical Engineering Healthcare Provider Healthcare 114

Pharmaceutical Technology

JUNE 5, 2023

According to GlobalData, Phase II drugs for Pancreatic Cancer have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Pralsetinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

Patients 40

Patients Medicine Healthcare Healthcare 40

Pharmaceutical Technology

FEBRUARY 24, 2023

According to Globaldata, it is involved in 10 clinical trials, of which 4 were completed, 5 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Retatrutide’s valuation in its risk-adjusted NPV model (rNPV). It is a new molecular entity.

Distribution 45

Distribution Medicine Sales Pharmaceutical 45

Pharmaceutical Technology

NOVEMBER 25, 2022

The global pharmaceutical industry experienced a 30% rise in new job postings related to cybersecurity in Q3 2022 compared with the previous quarter, according to GlobalData’s Jobs Analytics. This compares to a 30% increase in the previous quarter and a 70% increase versus Q3 2021.

Pharmaceutical 40

Pharmaceutical Healthcare Healthcare Medical 40

Pharmaceutical Technology

NOVEMBER 25, 2022

The global pharmaceutical industry experienced a 7% drop in new job postings related to artificial intelligence in Q3 2022 compared with the previous quarter, according to GlobalData’s Jobs Analytics. This compares to a 7% increase in the previous quarter and a 63% increase versus Q3 2021.

Pharmaceutical 40

Pharmaceutical Management Healthcare Healthcare 40

Pharmaceutical Technology

MARCH 31, 2023

This also demonstrates our confidence in the investment climate in Kenya and the importance of utilising mRNA technology to build resilience in healthcare security in Africa.” The company is also committed to establishing mRNA manufacturing facilities in Australia, Canada, the US and the UK.

Manufacturing 105

Manufacturing Government Medicine Healthcare 105

Pharmaceutical Technology

MAY 8, 2023

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. Probiotical is a manufacturer of probiotics and synbiotics products.

Leads 98

Leads Pharmaceutical Manufacturing Healthcare 98

Pharmaceutical Technology

FEBRUARY 10, 2023

Partly in response to such drugs, risk-sharing agreements (RSAs) have increased in popularity and aim to mitigate the risks of including high-cost drugs on reimbursement lists and healthcare plans. GlobalData takes this opportunity to review the various types of RSAs and their evolution over time.

Marketing 105

Marketing Medicine Leads Safety 105

Pharmaceutical Technology

MAY 31, 2023

More than half (54%) of the surveyed healthcare industry professionals indicated that their sentiment towards Brexit had become more negative. A Brexit survey conducted previously by GlobalData in 2021 found that the majority (60%) of the respondents had a more neutral sentiment towards Brexit at that point.

Healthcare 22

Healthcare Healthcare Manufacturing Medicine 22

Pharmaceutical Technology

MAY 16, 2023

UniQure is selling a part of its royalty rights to the haemophilia B gene therapy Hemgenix (etranacogene dezaparvovec) to HealthCare Royalty and Sagard Healthcare for a gross purchase price of up to $400 million dollars. HealthCare Royalty is a royalty acquisition company. HealthCare Royalty is a royalty acquisition company.

Food and Drug Administration 52

Food and Drug Administration Healthcare Healthcare Sales 52